Haichuang Pharmaceutical announced that clinical research data on the company's self-developed PROTAC drug HP518 will be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This drug is used to treat patients with advanced prostate cancer (mCRPC). The study showed that HP518 showed good safety and initial efficacy in 22 patients, 3 patients showed a PSA50 response, and 2 patients were partially relieved. The median peak time for drug blood concentrations was 3-12 hours, and no dose-limiting toxicity was observed.
海创药业：公司自主研发的PROTAC药物HP518临床数据在ASCO年会发布
Haichuang Pharmaceutical: Clinical data on the company's self-developed PROTAC drug HP518 was released at the ASCO annual meeting
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.